Companies ›Healthcare ›JUNS.O

JUNS.O — NASDAQ Pharmaceuticals & Medical Research

Jupiter Neurosciences Inc

$0,10

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

3,6M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

-40 865,7 %

ROE

471,9 %

Net margin

-39 655,5 %

Debt / equity

-2,89

Beta

—

52w range

—

Volume

7,6k

Day range

—

Prev close

$0,24

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Jupiter Neurosciences Inc is a biotechnology company focused on the development of therapies for neurological and psychiatric disorders, primarily through its lead candidate, JNJ-63733657, a selective orexin receptor antagonist for the treatment of insomnia.

Business. Jupiter Neurosciences Inc (JUNS.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals & Medical Research

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership→

Geode Capital Management, L.L.C.

largest disclosed fund holder

Profitability→

471,9 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning JUNS.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to JUNS.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Jupiter Neurosciences Inc (JUNS.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals & Medical Research

AI synthesis

GENERATED

Jupiter Neurosciences operates with a highly leveraged capital structure, as evidenced by its negative total equity of $1.83 million and a debt-to-equity ratio of -2.89. The company's liquidity position is weak, with a current ratio of 0.65 and negative operating cash flow of $5.41 million. The enterprise value to revenue ratio of 824.7 indicates a high valuation relative to its current revenue base of $21.8 million.

Profitability metrics are mixed. The company reported a gross profit of $17.57 million, but this was offset by an operating loss of $8.91 million and a net loss of $8.64 million. Return on equity is positive at 4.72%, but return on assets is negative at -1.55%, reflecting the company's high debt burden and negative equity position.

The company's revenue is concentrated in a single therapeutic area, with no disclosed geographic diversification. This lack of diversification increases exposure to regulatory and clinical risks associated with its lead candidate, JNJ-63733657.

Growth expectations are limited, with the company reporting a net loss in the most recent fiscal year and no disclosed revenue growth in the prior period. The outlook for the next fiscal year remains uncertain, with no material changes in revenue or earnings expected.

The company faces significant liquidity and solvency risks, with total liabilities exceeding total assets by $1.83 million. The risk assessment indicates a medium liquidity risk and a low dilution risk, though the negative net cash position raises concerns about the company's ability to fund operations without additional financing.

Recent filings and transcripts indicate ongoing clinical development of JNJ-63733657, with no material changes in the company's strategic direction. The company has not disclosed any new product candidates or partnerships in the latest investor communications.

Key takeaways

Jupiter Neurosciences is a biotechnology company with a high debt burden and negative equity.
The company's gross profit is offset by significant operating and net losses.
Revenue is concentrated in a single therapeutic area with no geographic diversification.
Liquidity is weak, with a current ratio of 0.65 and negative operating cash flow.
The company's growth trajectory is uncertain, with no material revenue or earnings growth expected.
The risk assessment highlights medium liquidity risk and a negative net cash position.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$0,10

Market cap

$12.7M

Enterprise valueⓘ

$18.0M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

-$1.8M

Net cashⓘ

-$5.3M

Current ratioⓘ

0.7

Debt / equityⓘ

-2.9

ROAⓘ

-1.6%

ROEⓘ

4.7%

Cash conversionⓘ

63.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs JUNS · multiples and returns

KLAR—

KLAR.ST

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

BNTX—

Biontech SE

$92,25

23,3B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

EXEL—

Exelixis Inc

$55,06

14,7B USD

P/E

19,5x

— vs self

Div yield

—

— vs self

ROE

40,4 %

-431,5 vs self

MDGL—

Madrigal Pharmaceuticals Inc

$482,00

11,0B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-47,8 %

-519,8 vs self

INSM—

Insmed Inc

$107,46

23,0B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-160,2 %

-632,1 vs self

VCYT—

Veracyte Inc

$45,30

3,6B USD

P/E

55,5x

— vs self

Div yield

—

— vs self

ROE

5,1 %

-466,8 vs self

MDXG—

Mimedx Group Inc

$4,27

636,0M USD

P/E

11,1x

— vs self

Div yield

—

— vs self

ROE

18,9 %

-453,0 vs self

AVIR—

Atea Pharmaceuticals Inc

$4,61

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

-57,5 %

-529,4 vs self

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin-40 865,7 %Bottom quartile

Net Margin-39 655,5 %Bottom quartile

ROE471,9 %Best in class

D/E-2,89Best in class

Cash Conv0,63Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 3 301 726 sh9 grants9 insiders

Weis HolgerDirector · Stock Option → Common StockAcquired 100 000 @ $0,28grant · 2026-06-02
Rosen Alexander Gustaf ErikChief Administrative Officer · Stock Option → Common StockAcquired 341 843 @ $0,28grant · 2026-06-02
Silva Alison D.Director, President and COO · Stock Option → Common StockAcquired 1 027 304 @ $0,28grant · 2026-06-02
Hayward Marshall A.Director, Chief Scientific Officer · Stock Option → Common StockAcquired 259 231 @ $0,28grant · 2026-06-02
Kampf Julie B.Director · Stock Option → Common StockAcquired 100 000 @ $0,28grant · 2026-06-02
Brady Allison WDirector · Stock Option → Common StockAcquired 100 000 @ $0,28grant · 2026-06-02
Elmasri SaleemChief Financial Officer · Stock Option → Common StockAcquired 525 565 @ $0,28grant · 2026-06-02
ROSEN CHRISTERDirector, CEO and Chairman · Stock Option → Common StockAcquired 747 783 @ $0,28grant · 2026-06-02
Hemmerly Nicholas H.Director · Stock Option → Common StockAcquired 100 000 @ $0,28grant · 2026-06-02

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Return On Equity
net_income / total_equity
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Ev To Revenue
enterprise_value / revenue
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt

Source documents

Jupiter Neurosciences Inc Market data — financials · 2026-05-28
Jupiter Neurosciences Inc Market data — analyst estimates · 2026-05-28

Ownership & reference

Top holders

Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$0M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M

Insider activity

Net buying5 buys · 0 sellsnet $4K2 insiders · last 365d

Silva Alison D.Director, Pres + Chief Business Officer · Common StockBought 250 @ $1,03$257 · 2025-07-01
Silva Alison D.Director, Pres + Chief Business Officer · Common StockBought 250 @ $1,03$257 · 2025-07-01
Silva Alison D.Director, Pres + Chief Business Officer · Common StockBought 250 @ $1,03$258 · 2025-07-01
ROSEN CHRISTERDirector, CEO and Chairman, 10% owner · Common StockBought 500 @ $1,01$505 · 2025-07-01
ROSEN CHRISTERDirector, CEO and Chairman, 10% owner · Common StockBought 3 100 @ $1,02$3K · 2025-07-01

Short positioning

239.1Kshares short-74.5% vs prior

1days to cover

35.0%short of daily vol

16.2Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

JUNS.OCanonical

NASDAQ · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 264.3%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -10.3%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -212.5%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -143.9%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): 323.5%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): -188.2%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -38.4%Derived (calculated)
Net margin (FY 2025-12-31): -39,662.8%Derived (calculated)
Gross margin (FY 2025-12-31): 80.6%Derived (calculated)
Return on equity (FY 2025-12-31): 471.9%Derived (calculated)
Return on assets (FY 2025-12-31): -155.4%Derived (calculated)
Current ratio (FY 2025-12-31): 0.65xDerived (calculated)
Debt-to-equity (FY 2025-12-31): -4.04xDerived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): -254.4%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -212.5%Derived (calculated)
Operating income (annual): USD -8.91MSEC XBRL filing
Revenue (annual): USD 21.8KSEC XBRL filing
Total assets (annual): USD 5.56MSEC XBRL filing
Total liabilities (annual): USD 7.4MSEC XBRL filing
R&D expense (annual): USD 2.09MSEC XBRL filing
EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
Cost of revenue (annual): USD 4.23KSEC XBRL filing
Total operating expenses (annual): USD 8.93MSEC XBRL filing
Gross profit (annual): USD 17.57KSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-29 22:34 UTCEVENTHa Price Listing JUNS remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 30 consecutive trading days (last close $0.223). cure deadline 2027-01-17 (172 days remaining).

2026-06-05FILING424B3 filing →

2026-06-05FILING8-K filing →

2026-06-02 00:00 UTCINSIDER9 insider transactions — 2026-06 9 derivative

2026-06-02INSIDERROSEN CHRISTER acquired 747.8k sh Stock Option — Director, CEO and Chairman

2026-06-02INSIDERHemmerly Nicholas H. acquired 100.0k sh Stock Option — Director

2026-06-02INSIDERKampf Julie B. acquired 100.0k sh Stock Option — Director

2026-06-02INSIDERBrady Allison W acquired 100.0k sh Stock Option — Director

2026-06-02INSIDERElmasri Saleem acquired 525.6k sh Stock Option — Chief Financial Officer

2026-06-02INSIDERSilva Alison D. acquired 1.03M sh Stock Option — Director, President and COO

2026-06-02INSIDERHayward Marshall A. acquired 259.2k sh Stock Option — Director, Chief Scientific Officer

2026-06-02INSIDERWeis Holger acquired 100.0k sh Stock Option — Director

2026-06-02INSIDERRosen Alexander Gustaf Erik acquired 341.8k sh Stock Option — Chief Administrative Officer

2026-05-21FILING424B3 filing →

2026-05-21FILING8-K filing →

2026-05-21FILING424B5 filing →

2026-05-20FILING424B3 filing →

2026-05-20FILING8-K filing →

2026-05-14FILING424B3 filing →

2026-05-14FILING10-Q filing →

2026-05-08FILING424B3 filing →

2026-04-01FILING10-K filing →

2025-07-02 00:00 UTCINSIDER7 insider transactions — 2025-07 2 derivative

2025-07-01INSIDERSilva Alison D. bought 250 sh — Director, Pres + Chief Business Officer ~$0k

2025-07-01INSIDERROSEN CHRISTER bought 500 sh — Director, CEO and Chairman, 10% owner ~$1k

2025-07-01INSIDERROSEN CHRISTER bought 3.1k sh — Director, CEO and Chairman, 10% owner ~$3k

2025-06-30 00:00 UTCINSIDER20 insider transactions — 2025-06

2025-01-22 00:00 UTCINSIDER4 insider transactions — 2025-01 2 derivative

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread